SATB1 and digestive system neoplasm: Besides breast cancer, aberrant expression of SATB1 was also correlated with advanced clinicopathologic factors and poor prognosis in cases of glioma, melanoma and carcinomas of stomach, rectum, liver, bladder, and prostate [17]–[21], [25]–[27].